On November 23, 2017, Fischer, John P.; Fell, Jay Bradford; Blake, James F.; Hinklin, Ronald Jay; Mejia, Macedonio J.; Hicken, Erik James; Chicarelli, Mark Joseph; Gaudino, John J.; Vigers, Guy P.A.; Burgess, Laurence E.; Marx, Matthew Arnold; Christensen, James Gail; Lee, Matthew Randolf; Savechenkov, Pavel; Zecca, Henry J. published a patent.Related Products of 175357-98-9 The title of the patent was Preparation of substituted pyridopyrimidines as KRas G12C inhibitors for treating cancer. And the patent contained the following:
The title compounds I [X = (un)substituted 4-12 membered saturated or partially saturated monocyclic, bridged or spirocyclic ring; Y = a bond, O, S or NR5; R1 = C(O)C(Ra)(๎ or =)C(Rb)p or SO2C(Ra)(๎ or =)C(Rb)p; R2 = H, alkyl, hydroxyalkyl, etc.; R3 = (independently) alkyl, oxo, haloalkyl; L = a bond, C(O), alkylene; R4 = H, cycloalkyl, heterocyclyl, etc.; R5 = (independently) H, alkyl; m = 0-2; Ra = absent, H, alkyl; each Rb = (independently) H, alkyl, alkylaminylalkyl, dialkylaminylalkyl or heterocyclylalkyl; p = 0 or 2] or a pharmaceutically acceptable salts thereof that inhibit KRas G12C, were prepared E.g., a multi-step synthesis of II, starting from tert-Bu 4-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate and benzyl 1-piperazinecarboxylate, was described. Exemplified compounds I were tested for inhibition of KRas G12C activity (data given). In particular, the present invention relates to compounds I that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds I and methods of use therefor. The experimental process involved the reaction of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine(cas: 175357-98-9).Related Products of 175357-98-9
The Article related to pyridopyrimidine preparation kras g12c inhibitor antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Related Products of 175357-98-9
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia